Oncoimmunology
Overview
Oncoimmunology is a peer-reviewed journal that focuses on the rapidly evolving field of cancer immunology. It publishes cutting-edge research articles, reviews, and commentaries that explore the interplay between the immune system and cancer, aiming to advance our understanding of tumor immunology and develop innovative immunotherapeutic strategies for cancer treatment.
Details
Details
Abbr.
Oncoimmunology
Start
2012
End
Continuing
Frequency
Bimonthly
p-ISSN
2162-4011
e-ISSN
2162-402X
Country
United States
Language
English
Specialty
Allergy & Immunology
Metrics
Metrics
h-index / Ranks: 2450
114
SJR / Ranks: 917
2345
CiteScore / Ranks: 868
12.50
JIF / Ranks: 831
7.2
Recent Articles
1.
Wang M, Zhang Z, Yang Y, Peng X, Yin H
Oncoimmunology
. 2025 Mar;
14(1):2478850.
PMID: 40085508
Targeted therapies leveraging the innate immune system are emerging as promising cancer treatments. The mitochondrial antiviral signaling protein (MAVS) plays a crucial role in initiating innate immune responses, but its...
2.
Phillips M, Alese O, Horvat N, Greene E, Gbolahan O, Coleman K, et al.
Oncoimmunology
. 2025 Mar;
14(1):2475620.
PMID: 40079916
We conducted a phase Ib/II clinical trial to evaluate the safety, feasibility, and clinical activity of combining pembrolizumab (anti-PD-1) with XL888 (Hsp90 inhibitor) in patients with advanced colorectal cancer (CRC)....
3.
Llopiz D, Silva L, Ruiz M, Castro-Alejos C, Aparicio B, Vegas L, et al.
Oncoimmunology
. 2025 Mar;
14(1):2473165.
PMID: 40029206
Immunotherapy with immune checkpoint inhibitors (ICI) in hepatocellular carcinoma (HCC) patients only achieves response rates of 25%-30%, indicating the necessity of new therapies for non-responder patients. Since myeloid-related suppressive factors...
4.
Davola M, Cormier O, Lepard M, McNicol J, Collins S, Hammill J, et al.
Oncoimmunology
. 2025 Feb;
14(1):2473163.
PMID: 40017442
Cancer immunotherapy promises to treat challenging cancers including -mutated colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC). However, pre-clinical animal models that better mimic patient tumor and immune system interactions...
5.
Chang M, Cheng J, Chen W, Shen Y, Kuo C, Chien R
Oncoimmunology
. 2025 Feb;
14(1):2470128.
PMID: 40008547
How mixed cryoglobulinemia (MC) affects cancer risk in chronic hepatitis C patients with sustained virologic response (SVR) remains unclear. In a 12-year prospective study, post-SVR MC was assessed every 3‒6 ...
6.
Roesel R, Strati F, Basso C, Epistolio S, Spina P, Djordjevic J, et al.
Oncoimmunology
. 2025 Feb;
14(1):2465015.
PMID: 39992705
Locally advanced rectal cancer (LARC) is treated with neoadjuvant chemo-radiotherapy (nCRT) followed by surgery. A minority of patients show complete response (CR) to nCRT and may avoid surgery and its...
7.
Rocha P, Bach R, Masfarre L, Hernandez S, Navarro-Gorro N, Rossell A, et al.
Oncoimmunology
. 2025 Feb;
14(1):2469377.
PMID: 39991958
Introduction: Immunotherapy is firmly established as a treatment regimen in various solid tumors, driven by its exceptional benefits in a selected group of patients. Despite widespread adoption of immune checkpoint...
8.
Greib A, Zhao S, Ploch M, Henricks J, Easterling R, Moodabagil M, et al.
Oncoimmunology
. 2025 Feb;
14(1):2469375.
PMID: 39981683
Immune checkpoint inhibitors (ICIs) are first line treatment for advanced lung cancer. Tobacco use is a shared risk factor for lung cancer and chronic obstructive pulmonary disease (COPD). Although many...
9.
Shohdy K, Atherton J, Longland J, Alison J, Pillai M, Thistlethwaite F
Oncoimmunology
. 2025 Feb;
14(1):2462386.
PMID: 39981665
Specific shared HLA-I alleles were linked to the response to immune checkpoint blockade (ICB). We aimed to identify the HLA-A subtypes associated with maximum benefit from ICB. We compiled a...
10.
Zhang X, Feng Z, Pranatharthi Haran A, Hua X
Oncoimmunology
. 2025 Feb;
14(1):2458843.
PMID: 39976474
Adoptive cell therapy including chimeric antigen receptor (CAR) T cells targeting CD19 has been approved by FDA to treat B cell-derived malignancies with remarkable success. The success has not yet...